Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Inclusion Criteria: * Vernal keratoconjunctivitis patients diagnosed by "Guideline of diagnosis and treatment of allergic conjunctival disease" * Patients with type I reactions defined by skin testing, antibody measurement, etc. * Age over 6 years old Exclusion Criteria: * Subjects receiving systemic administration or subconjunctival injection of corticosteroid or immunosuppressants(ophthalmic and systemic medications) within 2-weeks of initiation of the study * Subjects needed to wear contact lenses during treatment period on a testing eye * Subjects complicating an eye infection